Completed PHASE1 INTERVENTIONAL 5-arm NCT02712554

A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route

A Randomized, Double-Blind, Placebo and Active-Controlled, Crossover Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route

Sponsor: Charleston Laboratories, Inc

Conditions Nausea Pain Vomiting

Interventions CL-108 M366 Placebo

Updated 7 times since 2017 Last updated: Oct 11, 2019 Started: Jun 30, 2015 Primary completion: Sep 30, 2015 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02712554, this PHASE1 trial focuses on Nausea and Pain and remains completed. Sponsored by Charleston Laboratories, Inc, it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Nov 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Nov 2019 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Charleston Laboratories, Inc

Data source: Charleston Laboratories, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.